TC BioPharm (Holdings) PLC announced that the company's lead therapeutic TCB008 will be available to patients via a newly launched compassionate use program in the UK. Compassionate use refers to the prescription of unlicensed medicinal products to treat a patient in instances where their individual clinical needs cannot be met with the available licensed treatments. Patients enrolling in these clinical trials must meet specific entry criteria, both to protect vulnerable patient populations and ensure the validity of study data.

These data must be reviewed and approved by regulatory agencies before products can be marketed as licensed medicinal products for patient treatment. Access to TCB's cell therapy products through the compassionate use program will provide medical practitioners with treatment options for patients who are ineligible to access experimental treatments through ongoing clinical trials.